Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has released its financial results for the third quarter ending September 30, 2024, alongside key updates on its clinical trials. The company …
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is gearing up to participate in a series of fireside chats at notable investor conferences this fall. These events provide an opportunity …
Mineralys Therapeutics Set to Engage with Investors at Key Conferences Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is set to release its financial results for the third quarter of 2024 on Monday, November 11, after the market closes. Investors …
Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will …
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is set to participate in the Wells Fargo Healthcare Conference in Boston, MA.
Mineralys Therapeutics to Speak at Wells Fargo Healthcare Conference Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) this week announced its financial results for the second quarter ending June 30, 2024, and provided a corporate update, highlighting significant progress …
Mineralys Therapeutics Posts Q2 Financial Results, Updates on Clinical Trials Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will release its financial results for the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, …
Mineralys Therapeutics to Announce Q2 2024 Financial Results Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) announced the appointment of Alexander M. Gold, M.D., to its Board of Directors, effective June 13, 2024. His addition comes as the …
Mineralys Therapeutics Appoints Dr. Alexander Gold to Board Amid Hypertension Drug Development Read More